We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
+$71.8M
Cap. Flow
-$218M
Cap. Flow %
-1.26%
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$27.7M
2
ABCL icon
AbCellera Biologics
ABCL
+$26.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.1M
4
DNLI icon
Denali Therapeutics
DNLI
+$21.2M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$12.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$63.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$55.9M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$48.1M
4
IMGN
Immunogen Inc
IMGN
+$28.7M
5
ANAB icon
AnaptysBio
ANAB
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSHA icon
51
Taysha Gene Therapies
TSHA
$1.58B
$7.92M 0.05%
+2,504,756
New +$4.68M
SANA icon
52
Sana Biotechnology
SANA
$852M
$7.74M 0.04%
2,000,000
– –
BLUE
53
DELISTED
bluebird bio
BLUE
$7.6M 0.04%
124,986
– –
SPRY icon
54
ARS Pharmaceuticals
SPRY
$552M
$7.58M 0.04%
2,006,451
– –
SGMT icon
55
Sagimet Biosciences
SGMT
$435M
$7.18M 0.04%
+815,359
New +$10.9M
TCRX icon
56
TScan Therapeutics
TCRX
$48.1M
$7.13M 0.04%
2,784,792
– –
GERN icon
57
Geron
GERN
$911M
$6.49M 0.04%
3,061,224
– –
LONA
58
LeonaBio Inc
LONA
$66.4M
$6.37M 0.04%
315,381
– –
ALEC icon
59
Alector
ALEC
$169M
$6.25M 0.04%
964,851
– –
MIRM icon
60
Mirum Pharmaceuticals
MIRM
$6.58B
$6.02M 0.03%
+190,476
New +$5.22M
EWTX icon
61
Edgewise Therapeutics
EWTX
$4.26B
$6.01M 0.03%
1,049,699
+549,699
+110% +$3.74M
SMMT icon
62
Summit Therapeutics
SMMT
$9.88B
$5.87M 0.03%
3,140,473
-3,164,232
-50% -$6.03M
STOK icon
63
Stoke Therapeutics
STOK
$1.8B
$5.85M 0.03%
1,485,915
-644,323
-30% -$4.24M
HOOK
64
DELISTED
HOOKIPA Pharma
HOOK
$4.97M 0.03%
806,540
+363,986
+82% +$2.67M
MORF
65
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4.94M 0.03%
+215,800
New +$11.3M
CELC icon
66
Celcuity
CELC
$3.97B
$4.89M 0.03%
+535,478
New +$5.27M
NGNE icon
67
Neurogene
NGNE
$648M
$4.82M 0.03%
305,354
+114,267
+60% +$1.69M
WHWK
68
Whitehawk Therapeutics
WHWK
$181M
$4.79M 0.03%
989,928
– –
OPT
69
DELISTED
Opthea Limited American Depositary Shares
OPT
$4.69M 0.03%
2,690,891
-500
-0% -$1.33K
NTRA icon
70
Natera
NTRA
$35.9B
$4.42M 0.03%
100,000
– –
DSGN icon
71
Design Therapeutics
DSGN
$743M
$3.54M 0.02%
1,500,000
+1,000,000
+200% +$4.66M
PRAX icon
72
Praxis Precision Medicines
PRAX
$8.14B
$3.21M 0.02%
125,328
– –
CMPX icon
73
Compass Therapeutics
CMPX
$351M
$3.07M 0.02%
1,557,630
– –
TLIS
74
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$2.93M 0.02%
508,323
+1
+0% +$7
GRCL
75
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$2.88M 0.02%
1,000,000
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Baker Bros. Advisors held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
  • Baker Bros. Advisors added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
  • Baker Bros. Advisors's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
  • Baker Bros. Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 14 in Q3 2023.
  • Baker Bros. Advisors's portfolio value rose 0.42% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.